Date: 2013-02-28
Type of information: Collaboration agreement
Compound: Lauriad® mucoadhesive technology
Company: BioAlliance Pharma (France) undisclosed worldwide leader in vaccines
Therapeutic area: Infectious diseases
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On February 28, 2013, BioAlliance Pharma has announced a collaboration agreement with one of the world leading vaccine companies to develop a vaccine application of its Lauriad® mucoadhesive technology. The terms of this agreement are not disclosed at this time.
This research program aims at establishing the feasibility of using Lauriad® technology for vaccination, leading to an efficient needle-free administration based on the application to the gum of this mucoadhesive tablet containing a vaccine antigen. This project is carried out within the Fluriad™ consortium set in March 2011, co-labeled by both “Clusters of excellence” Medicen Paris Region and Atlanpôle Biotherapies and financed up to €2 million by the “Fond Unique Interministériel” (a French program supporting collaborative research projects).
Financial terms:
Latest news:
